Copyright
©The Author(s) 2023.
World J Clin Cases. Feb 6, 2023; 11(4): 738-755
Published online Feb 6, 2023. doi: 10.12998/wjcc.v11.i4.738
Published online Feb 6, 2023. doi: 10.12998/wjcc.v11.i4.738
Table 2 Baseline patient characteristics
| Characteristics | high-CD93 (n = 220) | low-CD93 (n = 114) | Overall (n = 334) |
| Age, yr (mean ± SD) | 64.8 ± 12.8 | 64.1 ± 10.3 | 64.5 ± 12.0 |
| Gender, n (%) | |||
| Female | 72 (32.7) | 48 (42.1) | 120 (35.9) |
| Male | 148 (67.3) | 66 (57.9) | 214 (64.1) |
| Grade, n (%) | |||
| G1 | 4 (1.8) | 4 (3.5) | 8 (2.4) |
| G2 | 66 (30.0) | 50 (43.9) | 116 (34.7) |
| G3 | 143 (65.0) | 59 (51.8) | 202 (60.5) |
| GX | 7 (3.2) | 1 (0.9) | 8 (2.4) |
| pT, n (%) | |||
| T1 | 5 (2.3) | 10 (8.8) | 15 (4.5) |
| T2 | 45 (20.5) | 25 (21.9) | 70 (21.0) |
| T3 | 103 (46.8) | 53 (46.5) | 156 (46.7) |
| T4 | 67 (30.5) | 26 (22.8) | 93 (27.8) |
| pN, n (%) | |||
| N0 | 63 (28.6) | 40 (35.1) | 103 (30.8) |
| N1 | 62 (28.2) | 24 (21.1) | 86 (25.7) |
| N2 | 43 (19.5) | 26 (22.8) | 69 (20.7) |
| N3 | 48 (21.8) | 22 (19.3) | 70 (21.0) |
| NX | 4 (1.8) | 2 (1.8) | 6 (1.8) |
| pM, n (%) | |||
| M0 | 194 (88.2) | 105 (92.1) | 299 (89.5) |
| M1 | 17 (7.7) | 4 (3.5) | 21 (6.3) |
| MX | 9 (4.1) | 5 (4.4) | 14 (4.2) |
| Stage, n (%) | |||
| Stage I | 24 (10.9) | 22 (19.3) | 46 (13.8) |
| Stage II | 75 (34.1) | 35 (30.7) | 110 (32.9) |
| Stage III | 96 (43.6) | 48 (42.1) | 144 (43.1) |
| Stage IV | 25 (11.4) | 9 (7.9) | 34 (10.2) |
- Citation: Li Z, Zhang XJ, Sun CY, Fei H, Li ZF, Zhao DB. CD93 serves as a potential biomarker of gastric cancer and correlates with the tumor microenvironment. World J Clin Cases 2023; 11(4): 738-755
- URL: https://www.wjgnet.com/2307-8960/full/v11/i4/738.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i4.738